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Background: Sentinel lymph node biopsy (SNB)-oriented stepwise treatment under local anesthesia has been
performed in the outpatient-ambulatory setting in patients receiving neoadjuvant therapy (NAT). We retrospectively
reviewed our preliminary experience of ambulatory SNB in breast cancer patients scheduled to undergo NAT to
evaluate the usefulness and feasibility of this method as a minimally invasive, stepwise treatment protocol.
Methods: We retrospectively identified 56 patients with breast cancer without obvious nodal involvement who
were scheduled to receive NAT before breast surgery. SNB was performed under local anesthesia in an ambulatory
outpatient setting before the initiation of NAT.
Results: The average number of removed sentinel lymph nodes was 1.9. Identification of the sentinel node was
possible in all cases, and macrometastasis was observed in six cases (10.7%). Micrometastasis was observed in five
cases, while isolated tumor cells were noted in six cases. There were no delays in the initiation of NAT as a result of
complications of SNB.
Conclusions: This pilot study demonstrated the safety and feasibility of ambulatory SNB prior to NAT. Further
studies are warranted to assess the strict indications, patient satisfaction, and medical economics of this procedure.
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Sentinel lymph node biopsy (SNB) in patients undergo-
ing breast cancer surgery (BCS) is currently regarded as
the standard minimally invasive strategy for managing
clinically node-negative early breast cancer [1-5]. Neoad-
juvant therapy (NAT) with chemo- or endocrine therapy
is usually administered with the aim of enabling BCS or
evaluating drug sensitivity in situ and is also regarded as
a standard treatment for operable breast cancer [6,7].
Nodal status is a major factor determining the suitability
of NAT. However, although SNB is considered to be an
accurate method for evaluating axillary nodal status as
an alternative to conservative axillary dissection, SNB* Correspondence: spqv9ke9@view.ocn.ne.jp
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unless otherwise stated.after NAT is less reliable, particularly in patients in
whom nodal involvement has been already detected
prior to NAT [8,9]. Several reports have therefore sug-
gested SNB prior to the initiation of NAT as a useful
strategy for assessing axillary nodal status [10-13]. How-
ever, the application of SNB before NAT requires add-
itional surgery and may result in delays in administering
NAT. We have applied an ambulatory SNB protocol that
allows NAT to be initiated based on an accurate histo-
logical diagnosis, including axillary nodal status, with
minimal patient burden, thus enabling the immediate
administration of NAT followed by BCS, with or without
hospitalization, in accordance with the patient’s needs.
SNB can be performed safely and adequately under local
anesthesia in the outpatient ambulatory setting, without
hospitalization [14-20]. A pathological diagnosis can then
be obtained from permanent preparations without the
need for intraoperative evaluation of frozen sections, inral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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false-negative diagnosis rate [5,21-23]. Furthermore, axil-
lary node dissection at surgery after NAT can be avoided
in patients with pathologically proven sentinel lymph node
(SN)-negative status [23-25].
In this study, we retrospectively reviewed our prelim-
inary experience of ambulatory SNB in breast cancer pa-
tients scheduled to undergo NAT and evaluated the
usefulness and feasibility of this method as an appropri-
ate, minimally invasive, stepwise treatment protocol.Methods
Patient characteristics
This study included 56 patients with a histologically con-
firmed diagnosis of invasive breast cancer following core
needle biopsy (CNB) of the tumor between April 2009 and
August 2013. All patients were scheduled for BCS following
the administration of NAT. Patients with clinical T2 tumors
in whom the absence of distant metastasis (M0) was con-
firmed by computed tomography (CT) and chest and abdo-
men and bone scintigraphy were enrolled. Patients with
multiple tumors or with a previous history of surgery to the
affected breast were excluded. Axillary nodal status was
evaluated by palpation, CT, and ultrasonography, and pa-
tients with obvious node metastasis were also excluded to
avoid unnecessary SNB. In these patients, lymph node me-
tastasis was confirmed by either fine needle aspiration cy-
tology or CNB of the affected nodes. Patients fulfilling the
inclusion criteria were provided with sufficient explanation
of the stepwise treatment plan (Figure 1), including the pro-
cedure for ambulatory SNB with local anesthesia.
This study was performed in accordance with the Dec-
laration of Helsinki and carried out with the approval of
the Ethical Review Board of Osaka City University (#926).
Sufficient explanation was provided and written informed
consent was obtained from all study subjects for theirFigure 1 Treatment plan. We administered a series of treatments, includi
ambulatory surgical procedures, followed by treatment with neoadjuvant t
breast cancer surgery (BCS). Ax: Axillary dissection.involvement in this study and for the storage and use of
their data.
Surgical procedure
SNs were identified by a combination of radioisotope
and dye methods [26]. For radioisotope examination,
intradermal and subcutaneous 99mTc-phytic acid colloid
1 mCi (1 mL) was injected into the skin overlying the
tumor and in the vicinity of the tumor the day before
ambulatory SNB. Lymphoscintigraphy was performed
4 h after injection (Figure 2a). For dye examination,
1.0 mL of 1% lidocaine (not containing epinephrine) was
added to 4.0 mL of indocyanine green (5 mg/mL) solu-
tion and injected intracutaneously in the areola of the af-
fected side (Figure 2b). Approximately 10 min after
injection, a skin incision (approximately 2 cm) was made
in the axilla under local anesthesia with 0.5% to 1.0%
lidocaine (containing 1:100,000 epinephrine) to identify
the blue node [14]. A hand-held gamma probe was used
to confirm the accumulation of radioactivity in the SN
injected the day before SNB. No drainage tubes were
placed. Pathological diagnosis of lymph node metastasis
was made by slicing the entire SN into 2-mm-thick sec-
tions, and a detailed pathological diagnosis was ob-
tained after conventional hematoxylin-eosin staining
associated with touch imprint cytology [27,28], by a
pathologist specializing in breast cancer. A positive
diagnosis of SN metastasis as an indication for axillary
clearance was defined as macrometastasis (i.e., tumor diam-
eter >2 mm) in the SN. Micrometastasis (i.e., tumor diam-
eter >0.2 mm, ≤2 mm, or <200 tumor cells) and isolated
tumor cells (ITC, i.e., tumor diameter <0.2 mm or <200
tumor cells) were determined as negative indications [29].
NAT was generally recommended according to the in-
trinsic subtype of the primary tumor determined from the
CNB sample, and axillary dissection was followed by BCS
under general anesthesia within 4 weeks after theng sentinel lymph node biopsy (SNB) under local anesthesia using
herapy (NAT) based on the histological diagnosis, and subsequent
Figure 2 Sentinel node examination. (a) Radioisotope examination: peritumoral injection of 99mTc-phytate 1 day before surgery. (b) Dye examination:
intradermal injection of indocyanine green in the areola.
Table 2 Results of sentinel lymph node biopsy
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axillary dissection was applied in SN-negative patients
with or without hospitalization, according to patient pref-
erence. Subsequent radiotherapy with 50 to 60 Gy was ad-
ministered to the residual mammary gland. Standard
adjuvant therapy was administered if indicated, according
to tumor subtype.
Results
All patients were female, with a median age of 59 (range
28 to 76) years. All SNB procedures were accomplished
under local anesthesia without conversion to general
anesthesia. No patients required hospitalization after SNB.
There were no complications of ambulatory SNB requir-
ing treatment, such as bleeding, infection, or lymphorrhea.
The average number of excised SNs was 1.9 ± 1.1 (Table 1),
and SN identification was possible in all cases.
Macrometastasis was detected in nine SNs in six pa-
tients (10.7%) (median diameter of metastatic lesion:
7.00 ± 2.20 mm). Micrometastasis was observed in ten
SNs in five patients (median diameter: 0.60 ± 0.23 mm),
and ITC was observed in ten SNs in six patients (median
length: 0.14 ± 0.06 mm) (Table 2). NAT was performed ac-
cording to each intrinsic subtype in all 56 patients after
evaluating the histological status of the axillary lymph node
metastasis. Neoadjuvant chemotherapy (NAC) was con-
ducted in 50 cases, resulting in 16 pathological complete
responses (pCRs), 29 pathological partial responses (pPRs),
and 5 cases of pathological stable disease (pSD). No cases
of pathological progressive disease (pPD) were observed.Table 1 Demographical data for 56 patients with
ambulatory sentinel lymph node biopsy undergoing
breast cancer treatment
Parameters (n = 56) Results
Age (years old) 59 ± 12
The average number of extracted SN 1.9 ± 1.1
Tumor location right/left 25 (44.6%)/31 (55.4%)
SN sentinel lymph node.Endocrine therapy was administered in six cases, resulting
in no pCRs or pPDs, two cases of pPR, and four cases of
pSD. BCS with axillary lymph node dissection was subse-
quently carried out as the second-phase surgical treatment
in six SNB-positive patients, and further, axillary lymph
node involvement was found in two of these six patients.
Three additional nodes were found to be involved during
axillary lymph node dissection after NAT in one patient
with a single positive SN before NAT. Two additional
metastatic nodes were found after NAT in another patient
with three positive SNs before NAT. No additional axillary
lymph node metastases were found in the other four pa-
tients who underwent axillary lymph node dissection
(Table 3). BCS without axillary lymph node dissection was
performed in the remaining 50 patients, including 7 pa-
tients under local anesthesia and 43 patients under general
anesthesia. All patients remained alive without disease after
a median follow-up period of 28 (range 3 to 52) months
since BCS.
Discussion
The long-term prognosis of SNB patients is not affected
by omitting axillary lymph node dissection, according to
the results of the large-scale clinical trial NSABP B-32
[23]. SNB-oriented management of axillary lymph nodeMetastasis negative
No metastasis 39 79
ITC 6 10 0.14 ± 0.06
Micrometastasis 5 10 0.60 ± 0.23
Metastasis positive
Macrometastasis 6 7 7.00 ± 2.20
Total 56 106
SN sentinel lymph node. Macrometastasis (tumor diameter >2 mm);
micrometastasis (tumor diameter >0.2 mm, ≤2 mm, or <200 tumor cells); ITC
(isolated tumor cell; tumor diameter <0.2 mm or <200 tumor cells).
Table 3 Results of axillary node dissection
Patient #












1 1 1 12 3
2 1 1 12 0
3 1 1 9 0
4 2 1 8 0
5 2 2 8 0
6 3 1 13 2
Total 10 7 62 5
SN sentinel lymph node.
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vasive surgical strategy for controlling local disease and
evaluating the pathological stage in patients with clinic-
ally node-negative, early breast cancer [1-5]. General
anesthesia is contraindicated in some patients because of
co-morbidities or a desire for ambulatory or short-stay
surgery. We therefore developed an ambulatory SNB-
oriented stepwise treatment strategy for such patients, as
described in this study. Surgical methods for performing
axillary lymph node dissection under local anesthesia
have been reported previously, but the procedure can re-
sult in insufficient dissection because of unsatisfactory
analgesia [19,20]. General anesthesia is therefore neces-
sary for standard axillary lymph node dissection. SNB,
however, can be carried out adequately and safely under
local anesthesia, as described in the present study
[14-18]. The existence and number of lymph node me-
tastases are major prognostic factors [30,31], and obtain-
ing an accurate diagnosis is mandatory for selecting
patients who require additional systemic therapy after
surgery. The false-negative rate of SNB for breast cancer
is reported to be 7% to 9%, based on the results of meta-
analyses [5,21-23]. The major reason for failure with re-
spect to pathological misdiagnosis is thought to involve
inadequate intraoperative tissue diagnosis associated with
the limitations of tissue-preparation conditions during sur-
gery using frozen specimens. Accordingly, non-definitive
results have been demonstrated in 3% to 35% of cases
[27,32-35]. These false-negative or indeterminate results
may be avoided by standard pathological investigations
using formalin-fixed paraffin-embedded samples obtained
by ambulatory SNB under local anesthesia.
The administration of NAT may affect the accuracy of
SNB. Two large-scale studies demonstrated that per-
forming SNB after NAC was not recommended in pa-
tients with apparent axillary lymph node involvement
before treatment because of the lower detection and
higher false-negative rates (SENTINA trial 14.2%, ACO-
SOG Z1071 trial 12.6%) of SNB after NAC [36,37]. Atthe same time, the authors suggested that patients with-
out nodal disease may be candidates for SNB after NAC
to avoid repeated surgery, delays in the initiation of
NAC, and possible unnecessary axillary dissection in
cases where total eradication of nodal disease has been
achieved by NAC. Although controversies remain, SNB
prior to NAT represents the most reliable way to evalu-
ate axillary lymph node metastasis in patients scheduled
for NAT. This procedure could help to predict the effect
of NAT on the involved axillary lymph nodes by con-
firming pathological nodal involvement before NAT.
Ambulatory SNB may also minimize the burden on the
patient with respect to repeated surgery and delays in
administering NAT, as demonstrated in the present
study. Furthermore, intimate pathological review of the
involved node may aid precise stratification of the pa-
tients for additional therapy and follow-up protocols
after scheduled NAT and BCS. The current study did
not evaluate the appropriate indications for SNB in pa-
tients in whom NAT failed, and this issue remains a con-
cern. Patients demonstrating resistance to NAT may
require changes in their treatment strategy from chemo-
therapy to surgical therapy to achieve sufficient disease
control. Among such cases, even in those with previous
negative results on SNB, simultaneous axillary lymph
node dissection may be necessary to confirm negative
node involvement and establish complete local control
by salvage surgery.
According to the results of the recent Z0011 trial [38],
clinicians must reconsider the need for complete axillary
dissection in SNB-positive patients with clinically node-
negative, early breast cancer scheduled for BCS with ra-
diation and adjuvant therapy, as demonstrated in the
present study. Furthermore, the present results also indi-
cate the possibility of skipping SNB in such cases,
though further investigations with longer observation
periods are required. However, our SNB-oriented step-
wise treatment protocol is likely to be beneficial in pa-
tients with clinically node-negative, early breast cancer,
by offering a sufficient but minimally invasive treatment
strategy based on accurate pathological staging.
Conclusions
This pilot study demonstrated the safety and feasibility
of ambulatory SNB prior to NAT in patients with oper-
able breast cancer. Future studies, including the deter-
mination of strict indications, assessments of patient
satisfaction, and medical economics, are warranted.Abbreviations
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